{"id":467,"date":"2017-12-19T14:26:21","date_gmt":"2017-12-19T19:26:21","guid":{"rendered":"https:\/\/sites.bu.edu\/evaluatingaccess-novartisaccess\/?page_id=467"},"modified":"2022-02-22T16:53:09","modified_gmt":"2022-02-22T21:53:09","slug":"data","status":"publish","type":"page","link":"https:\/\/sites.bu.edu\/evaluatingaccess-novartisaccess\/kenya\/data\/","title":{"rendered":"Data"},"content":{"rendered":"

Overview of Datasets<\/strong><\/p>\n

For detailed description of the evaluation the Novartis Access program, please refer to the published study protocol<\/a> or ClinicalTrials.gov<\/a>. The data collection instruments and the data dictionary are also available here<\/a>.<\/p>\n

Datasets from baseline and midline are now available. Baseline and midline studies each have one dataset for households and one for health facilities and private drug sellers. Baseline data were collected from eight counties in Kenya in September 2016. Midline data were collected in January 2018. Each data set comes with a data dictionary that describes all included variables. If you have any questions regarding the data, please contact Peter Rockers at prockers@bu.edu<\/a> or Richard Laing at richardl@bu.edu<\/a>.<\/p>\n

Baseline\u00a0<\/u>household\u00a0<\/u>data<\/u><\/span>: Data were collected through face-to-face interviews with individual adult patients who reported having been diagnosed with asthma, breast cancer, diabetes or cardiovascular disease (heart failure, hyperlipidemia, or hypertension) and prescribed at least one medicine for their condition. This dataset contains observations from 639 patients.<\/p>\n

Baseline health facility\u00a0<\/u>data<\/u>: Data were collected through face-to-face interviews with staff at 272 health facilities (59 public health facilities, 78 private non-profit health facilities, 135 private-for-profit drug outlets (chemists)) in the eight study counties. Key variables include price and availability data on 15 generic equivalents of Novartis Access medicines and 13 other essential medicines (tracer medicines which have been used as reference medicines to evaluate the availability of price of medicines in different healthcare systems).<\/p>\n

Midline\u00a0household\u00a0data<\/span>: The midline household data set contains follow-up data from 572 of the patients interviewed at baseline. Midline questions and methods are similar to those used at baseline.<\/p>\n

Midline health facility\u00a0<\/u>data<\/u>: The midline health facility data set contains follow-up data from 225 of the outlets interviewed at baseline\u00a0(61 public health facilities, 67 private non-profit health facilities, 97 private-for-profit drug outlets).\u00a0Midline questions and methods are similar to those used at baseline.<\/p>\n

Endline\u00a0household\u00a0data<\/span>: The endline household data set contains follow-up data from 516 of the patients interviewed at baseline. Endline questions and methods are similar to those used at baseline.<\/p>\n

Endline health facility\u00a0<\/u>data<\/u>: The endline health facility data set contains follow-up data from 221 of the outlets interviewed at baseline (57 public health facilities, 70 private non-profit health facilities, 94 private-for-profit drug outlets). Endline questions and methods are similar to those used at baseline.<\/p>\n

Surveillance household data<\/span>: The telephone surveillance household data set contains follow-up data from 612 of the patients interviewed at baseline. Surveillance questions and methods are similar to those used at baseline.<\/p>\n

Please provide the following information below so that we may send you the datasets via email.<\/p>\n

Please also note the Terms of Use, Recommended Citation, and Disclaimer at the bottom of this page.<\/p>\n